Replies to post #152168 on Biotech Values

[mcbio]

In this fiercely competitive landscape, slow, steady progress is tantamount to losing ground, so the selloff in ACHN’s shares today may be justified.

I think you have to ask yourself at what point does wanting to maximize the value of your in-house drugs cross that line of being by default because none of your competitors have shown interest in your drugs? ACHN continues to be passed over for the competition's drugs for HCV combo trials with Medivir's simeprevir being the latest example.